BioInsights - Supply chain challenges and issues facing the autologous cell manufacturing industry
Global cell and gene therapy supply chain strategies at commercial scale

Supply chain challenges and issues facing the autologous cell manufacturing industry

Cell & Gene Therapy Insights 2020; 6(2), 137-141.

10.18609/cgti.2020.018

Published: 23 April 2020
Expert Insight
Kan Wang, Ben Wang, Chelsea White, Aaron Levine

We discuss three supply chain challenges and issues facing the autologous cell manufacturing industry that may impact patient outcome and supply chain performance in a commercial setting. These are (i) the potential value of giving priority to the sickest patients with respect to the start of manufacturing their therapy, (ii) determining the optimal manufacturing capacity and reagent replenishment policy for a single cell manufacturing facility, given demand forecasts and patient service levels, and (iii) the resilience of reconfigurable supply chain networks for supply chains with geographically distributed manufacturing capacity.